Hidetomo Nakamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hidetomo Nakamoto has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Hiromichi Suzuki
Department of Nephrology, Saitama Medical School, Saitama
2 shared publicationsYoshindo Kawaguchi
Department of Nephrology, Kanagawa Prefectural Hospital, Japan
2 shared publications- Ayumi Yoshifuji
Department of Infectious Diseases, Keio University School of Medicine
1 shared publication Chieko Hamada
1 shared publication- Emi Oyama
Department of Nephrology, Tokyo Saiseikai Central Hospital, Tokyo 108-0073, Japan
1 shared publication - Fumihiko Hinoshita1 shared publication
Latest Publications
- Open Access
- 7 September 2022
- Published by MDPI AG in Preprints.org
T-cell Response and Antibody Production by Booster COVID-19 Vaccination in Japanese Patients with Chronic Kidney Disease Treated with Hemodialysis
Most studies on vaccines of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have focused on antibody, but cellular immunities are also critical. We aimed to evaluate the immune reactions of hemodialysis (HD) patients after the administration of the booster dose from the perspective of both humoral and cellular immunities. Hemodialysis patients (HD group) and age- and sex-matched non-dialysis individuals (control group) receiving three doses of BNT162b2 vaccine were measured for anti-SARS-CoV-2 immunoglobulin (IgG) and T-SPOTⓇ.COVID test (T-SPOT) before, 3 weeks, and 3 months after the booster dose. The HD group had significantly higher SARS-CoV-2 IgG levels 3 weeks and 3 months after the booster dose than the control group, although both groups had no difference in SARS-CoV-2 IgG levels before the booster dose. Moreover, the HD group had significantly higher T-SPOT levels before and 3 weeks after the booster dose than the control group, but the difference was not significantly different 3 months after the booster dose. Furthermore, the incidence rates of local and systemic adverse reactions were significantly higher in the HD group than in the control group. HD patients obtained higher SARS-CoV-2 IgG levels and SARS-COV-2-specific T-cell responses after the booster dose than control.
- 7 September 2022
- Published by MDPI AG in Preprints.org
Open AccessT-cell Response and Antibody Production by Booster COVID-19 Vaccination in Japanese Patients with Chronic Kidney Disease Treated with Hemodialysis
Most studies on vaccines of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have focused on antibody, but cellular immunities are also critical. We aimed to evaluate the immune reactions of hemodialysis (HD) patients after the administration of the booster dose from the perspective of both humoral and cellular immunities. Hemodialysis patients (HD group) and age- and sex-matched non-dialysis individuals (control group) receiving three doses of BNT162b2 vaccine were measured for anti-SARS-CoV-2 immunoglobulin (IgG) and T-SPOTⓇ.COVID test (T-SPOT) before, 3 weeks, and 3 months after the booster dose. The HD group had significantly higher SARS-CoV-2 IgG levels 3 weeks and 3 months after the booster dose than the control group, although both groups had no difference in SARS-CoV-2 IgG levels before the booster dose. Moreover, the HD group had significantly higher T-SPOT levels before and 3 weeks after the booster dose than the control group, but the difference was not significantly different 3 months after the booster dose. Furthermore, the incidence rates of local and systemic adverse reactions were significantly higher in the HD group than in the control group. HD patients obtained higher SARS-CoV-2 IgG levels and SARS-COV-2-specific T-cell responses after the booster dose than control.
- Open Access
- 1 March 2006
- Published by SAGE Publications in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
- Vol. 26 (2) , 136-143
Is Technique Survival on Peritoneal Dialysis Better in Japan?
Technique failure resulting in transfer to hemodialysis (HD) remains one of the most important challenges in long-term peritoneal dialysis (PD). In general, the proportion of patients transferring from PD to HD is much greater than the proportion transferring from HD to PD. However, technique failure rates differ considerably between and within countries. The question arises as to how technique failure rates in Japan compare with those in other countries. To address this issue, we reviewed the literature and our experience of 139 incident continuous ambulatory peritoneal dialysis (CAPD) patients from January 1995 to December 1999. Based on our review, we estimate that the 5-year technique survival rate in Japanese CAPD patients is approximately 70%, and that technique failure rate is around 7% per year. This rate is significantly lower than that in many other countries. The most common reasons for technique failure in Japan are peritoneal membrane failure, ultrafiltration loss, and inadequate dialysis. Another factor contributing to the low technique failure rate in Japan is an extremely low peritonitis rate. This may be related to good sanitation and excellent PD training programs. Peritoneal membrane failure continues to be the major challenge for long-term technique survival on PD in Japan.
- 1 March 2006
- Published by SAGE Publications in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
- Vol. 26 (2) , 136-143
Open AccessIs Technique Survival on Peritoneal Dialysis Better in Japan?
Technique failure resulting in transfer to hemodialysis (HD) remains one of the most important challenges in long-term peritoneal dialysis (PD). In general, the proportion of patients transferring from PD to HD is much greater than the proportion transferring from HD to PD. However, technique failure rates differ considerably between and within countries. The question arises as to how technique failure rates in Japan compare with those in other countries. To address this issue, we reviewed the literature and our experience of 139 incident continuous ambulatory peritoneal dialysis (CAPD) patients from January 1995 to December 1999. Based on our review, we estimate that the 5-year technique survival rate in Japanese CAPD patients is approximately 70%, and that technique failure rate is around 7% per year. This rate is significantly lower than that in many other countries. The most common reasons for technique failure in Japan are peritoneal membrane failure, ultrafiltration loss, and inadequate dialysis. Another factor contributing to the low technique failure rate in Japan is an extremely low peritonitis rate. This may be related to good sanitation and excellent PD training programs. Peritoneal membrane failure continues to be the major challenge for long-term technique survival on PD in Japan.
- 10 October 2005
- Published by Wiley in Hemodialysis International
- Vol. 9 (s4) , S2-S7
Role of platelet factor 4–heparin complex antibody (HIT antibody) in the pathogenesis of thrombotic episodes in patients on hemodialysis
Heparin‐induced thrombocytopenia (HIT) is a severe complication in patients on hemodialysis (HD). It has been reported that platelet factor‐4 (PF‐4)–heparin complex antibody (HIT antibody) plays an important role in the pathogenesis of this serious complication. In the present study, we investigated the role of HIT antibody in the pathogenesis of thrombotic complications including shunt failure, cerebrovascular disease (CVD) and atherosclerosis in patients on dialysis. Plasma concentration of HIT antibody in patients on HD was 0.143±0.008 (n=105). This was significantly higher in patients on continuous ambulatory peritoneal dialysis (CAPD: 0.087±0.006, p=0.0008, n=22) and in non‐dialysis patients (0.113±0.011, p=0.0011, n=12). There was a significant negative correlation between HIT antibody and the duration of dialysis. However, no significant correlation was found between HIT antibody and other factors including age, dose of heparin, platelet count and hemoglobin. There was a significant correlation between the number of failed arteriovenous fistula and HIT antibody levels. In addition, in patients with a history of CVD, plasma concentrations of HIT antibody were significantly higher compared with patients without CVD (CVD(+): 0.200±0.029 vs. (−): 0.127±0.005, p<0.0001). It is possible that genetic factors may also play a role in the expression of HIT antibody. From these data, it appears possible that HIT antibody plays an important role in the pathogenesis of thrombosis in patients on HD. Further studies are needed to clarify the role of HIT antibody in the pathogenesis of thrombotic episodes in these patients.
- 10 October 2005
- Published by Wiley in Hemodialysis International
- Vol. 9 (s4) , S2-S7
Role of platelet factor 4–heparin complex antibody (HIT antibody) in the pathogenesis of thrombotic episodes in patients on hemodialysis
Heparin‐induced thrombocytopenia (HIT) is a severe complication in patients on hemodialysis (HD). It has been reported that platelet factor‐4 (PF‐4)–heparin complex antibody (HIT antibody) plays an important role in the pathogenesis of this serious complication. In the present study, we investigated the role of HIT antibody in the pathogenesis of thrombotic complications including shunt failure, cerebrovascular disease (CVD) and atherosclerosis in patients on dialysis. Plasma concentration of HIT antibody in patients on HD was 0.143±0.008 (n=105). This was significantly higher in patients on continuous ambulatory peritoneal dialysis (CAPD: 0.087±0.006, p=0.0008, n=22) and in non‐dialysis patients (0.113±0.011, p=0.0011, n=12). There was a significant negative correlation between HIT antibody and the duration of dialysis. However, no significant correlation was found between HIT antibody and other factors including age, dose of heparin, platelet count and hemoglobin. There was a significant correlation between the number of failed arteriovenous fistula and HIT antibody levels. In addition, in patients with a history of CVD, plasma concentrations of HIT antibody were significantly higher compared with patients without CVD (CVD(+): 0.200±0.029 vs. (−): 0.127±0.005, p<0.0001). It is possible that genetic factors may also play a role in the expression of HIT antibody. From these data, it appears possible that HIT antibody plays an important role in the pathogenesis of thrombosis in patients on HD. Further studies are needed to clarify the role of HIT antibody in the pathogenesis of thrombotic episodes in these patients.
- Open Access
- 1 April 2005
- Published by SAGE Publications in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
- Vol. 25 (4_suppl) , 30-38
Encapsulating Peritoneal Sclerosis—A Clinician's Approach to Diagnosis and Medical Treatment
Encapsulating peritoneal sclerosis (EPS) is recognized as a serious complication of continuous peritoneal dialysis. A preliminary diagnosis of EPS is usually based on clinical signs and symptoms, which commonly include abdominal pain, nausea, vomiting, anorexia, abdominal fullness, an abdominal mass, bowel obstruction, and radiologic findings, including abdominal roentgenogram, contrast studies, ultrasound studies, and computed tomography. The diagnosis is confirmed by laparoscopy or laparotomy showing the characteristic gross thickening of the peritoneum enclosing some or all of the small intestine in a cocoon of opaque tissue. A variety of therapeutic approaches to EPS have been reported. This review discusses medical treatment of EPS and includes an overview of the clinical features and diagnostic aspects of the condition.
- 1 April 2005
- Published by SAGE Publications in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
- Vol. 25 (4_suppl) , 30-38
Open AccessEncapsulating Peritoneal Sclerosis—A Clinician's Approach to Diagnosis and Medical Treatment
Encapsulating peritoneal sclerosis (EPS) is recognized as a serious complication of continuous peritoneal dialysis. A preliminary diagnosis of EPS is usually based on clinical signs and symptoms, which commonly include abdominal pain, nausea, vomiting, anorexia, abdominal fullness, an abdominal mass, bowel obstruction, and radiologic findings, including abdominal roentgenogram, contrast studies, ultrasound studies, and computed tomography. The diagnosis is confirmed by laparoscopy or laparotomy showing the characteristic gross thickening of the peritoneum enclosing some or all of the small intestine in a cocoon of opaque tissue. A variety of therapeutic approaches to EPS have been reported. This review discusses medical treatment of EPS and includes an overview of the clinical features and diagnostic aspects of the condition.
- 1 January 2005
- Vol. 21, 168-74
Successful use of icodextrin in elderly patients on continuous ambulatory peritoneal dialysis.
In peritoneal dialysis (PD), a 7.5% polyglucose-containing dialysis solution (icodextrin) provides prolonged ultrafiltration as compared with glucose-based dialysis solutions. In the present study, we attempted to clarify the safety and effectiveness of icodextrin in elderly patients on continuous ambulatory peritoneal dialysis (CAPD). Clinical data and outcomes of 16 patients aged 65 or older were monitored for 12 weeks before and during icodextrin treatment. The group included 13 men and 3 women with a mean age of 69 +/- 5 years (range: 66-78 years). The underlying kidney disease was chronic nephritis in 7 patients, diabetes mellitus in 8 patients, and nephrosclerosis in I patient. From the beginning of peritoneal dialysis, 1 patients had been treated with icodextrin; the other 10 were changed to icodextrin from glucose dialysis solution. At the end of study, body weight had increased to 63.8 +/- 9.3 kg from 61.6 +/- 9.3 kg, accompanied by an increase in ultrafiltration to 480 +/- 207 mL daily from 369 +/- 436 mL daily. No significant change in urine volume occurred. Despite the increase in body weight, cardiothoracic rate decreased to 51.1% +/- 3.4% from 52.3% +/- 4.9%. All patients reported an improvement of edema and appetite. Edema scores were significantly decreased to 0.85 +/- 0.90 from 1.63 +/- 0.96 (p < 0.03). No adverse side effects were associated with the use of icodextrin. From the foregoing data, we concluded that, as compared with conventional glucose solution, icodextrin has beneficial effects on ultrafiltration volume and clinical symptoms in elderly patients on CAPD.
- 1 January 2005
- Vol. 21, 168-74
Successful use of icodextrin in elderly patients on continuous ambulatory peritoneal dialysis.
In peritoneal dialysis (PD), a 7.5% polyglucose-containing dialysis solution (icodextrin) provides prolonged ultrafiltration as compared with glucose-based dialysis solutions. In the present study, we attempted to clarify the safety and effectiveness of icodextrin in elderly patients on continuous ambulatory peritoneal dialysis (CAPD). Clinical data and outcomes of 16 patients aged 65 or older were monitored for 12 weeks before and during icodextrin treatment. The group included 13 men and 3 women with a mean age of 69 +/- 5 years (range: 66-78 years). The underlying kidney disease was chronic nephritis in 7 patients, diabetes mellitus in 8 patients, and nephrosclerosis in I patient. From the beginning of peritoneal dialysis, 1 patients had been treated with icodextrin; the other 10 were changed to icodextrin from glucose dialysis solution. At the end of study, body weight had increased to 63.8 +/- 9.3 kg from 61.6 +/- 9.3 kg, accompanied by an increase in ultrafiltration to 480 +/- 207 mL daily from 369 +/- 436 mL daily. No significant change in urine volume occurred. Despite the increase in body weight, cardiothoracic rate decreased to 51.1% +/- 3.4% from 52.3% +/- 4.9%. All patients reported an improvement of edema and appetite. Edema scores were significantly decreased to 0.85 +/- 0.90 from 1.63 +/- 0.96 (p < 0.03). No adverse side effects were associated with the use of icodextrin. From the foregoing data, we concluded that, as compared with conventional glucose solution, icodextrin has beneficial effects on ultrafiltration volume and clinical symptoms in elderly patients on CAPD.